bioeconomy The global bioeconomy is about to take off as manufacturers choose biology as the method of choice to efficiently produce high-performance, sustainable products. Synthetic biology is at leading edge of this $4 trillion gold rush. SYNBIOBETA
Home » Featured Slider » New McKinsey Report Sees A $4 Trillion Gold Rush In This One Hot Sector. Who’s Selling Picks And Shovels?

New McKinsey Report Sees A $4 Trillion Gold Rush In This One Hot Sector. Who’s Selling Picks And Shovels?

The global bioeconomy is about to take off as manufacturers choose biology as the method of choice to efficiently produce high-performance, sustainable products. Synthetic biology is at leading edge of this $4 trillion gold rush.

Here’s a little secret: the world increasingly depends on biological engineering to make useful products that are more sustainable and higher performance than can be extracted from the environment.

Most of us don’t realize that the objects in our everyday lives—the food we eat, the fashions we wearthe medicines we depend on, and so much more—rely on our ability not to simply extract products from the earth, but rather to harness biology itself to manufacture useful things.

Synthetic biology can take a little credit for that. Though few people know about it, synthetic biology is a field dedicated to making biology easier to engineer. It applies advances in computation, automation, and biology to biomanufacture solutions that are faster, cheaper, and better than conventional methods.

Enabling technologies have exponential impact

Like the internet, synthetic biology is a kind of enabling technology that drives radical changes in diverse industries. But unlike the internet, instead of just moving ones and zeros around, biology moves atoms—the very stuff of matter. The internet drives commerce and communications. And now, synthetic biology is about to drive the physical world.

So as companies look to biology for cheaper, more sustainable ways to make superior products, the biomanufacturing gold rush will begin, and synthetic biology will be selling the picks and shovels.

Next week, I am leading the Built With Biology Bioeconomy Summit of nearly 1,000 innovators, investors, and policymakers to discuss how biological innovations can shape a more resilient, sustainable, and prosperous economy for all. This will include discussion of The Endless Frontier Act, a just-released $100 billion bipartisan, bicameral bill led by Congressman Ro Khanna (D-CA), Senate Democratic Leader Chuck Schumer (D-NY), Senator Todd Young (R-IN), and Congressman Mike Gallagher (R-WI). Its aim: to strategically advance science and tech R&D—specifically including synthetic biology—to reinvigorate the post-COVID economy.

For a sense of just how synthetic biology figures into all of this, let’s take a look at how the internet and a couple of other enabling technologies have grown up, and compare them to the bioeconomy.

#1: The PC industry

The personal computer industry has grown tremendously since its introduction in the late 1970s. The first personal computer—the MITS Altair 8080—was released in 1975 with only a few thousands sales. It was a humble beginning to something that would change our world forever. The PC industry truly began its takeoff in the late 90s, as $7.4 billion were invested between 1985 and 1995. The PC industry peaked in 2011-2012 at a $300 billion annual market. Today, the PC is an essential tool found in most homes and offices, with more than 350 million units sold each year.

#2 The internet

In the early 1990’s another industry began to take off: the internet industry. Between 1995 and 2005 approximately $54 billion was invested in dot-coms. In 2010, ITIF estimated the annual global economic benefits of the commercial Internet at $1.5 trillion in 2010. Today, four dot-com-era companies are each worth over $1 trillion: Apple, Amazon, Microsoft, and Google parent company Alphabet.

#3 The mobile industry

If someone with big hair in the nineties told you that pretty soon you’d be carrying a phone in your pocket with as much power as a supercomputer, you’d probably think they were crazy. The mobile industry invests a whopping 23% of revenues into R&D, about $100 billion every year. That’s even more than the pharmaceutical industry (14%) but not quite as much as biotechnology (27%). This helped spawn the mobile apps market—now the fastest growing segment of the industry—which alone is expected to reach nearly $200 billion in 2020. Global revenue from smartphone sales amounted to almost $500 billion in 2017.

How do synthetic biology and the bioeconomy compare?

funding by year

Though synthetic biology is a young field, investment in the industry topped $18 billion in the last decade. SYNBIOBETA

The synthetic biology industry itself is still young, with $18 billion invested from 2010-2019, and market estimates at anywhere from $5 billion to $15 billion today. But like the internet, the real value to society is in all the other parts of the economy that it impacts. So how do we put a number on the impact of synthetic biology—and biological innovation more generally—on the economy as a whole?

In the U.S, the National Academies of Science, Engineering and Medicine took up this question in its January 2020 report, Safeguarding the Bioeconomy. It estimated that, in the U.S. alone, the bioeconomy measured about $1 trillion, with a potential size of about $1.4 trillion based on the portion of the economy that could be made bio-based using existing technology (e.g., plastics that could be made through a bio-based process today). That would amount to about 7.4% of the U.S.’s entire GDP.

A recent McKinsey study led by Michael Chui also tries to answer this question from a global perspective. It looked at the impact of about 400 applications of biological innovation in the pipeline today. Like the National Academies report, Chui’s team wasn’t talking about far-out ideas, but rather projects that are scientifically feasible now using today’s technology. Chui concluded that those 400 biology applications alone could have a direct global impact of up to $4 trillion per year over the next 10-20 years.

These numbers are pretty remarkable—far bigger than the economic impact of the internet.

The real value of biological innovation

As an enabling technology, synthetic biology has a clear potential to provide an outsized impact on the global economy, from biochemicals to biomedical goods to agriculture. If sectors like the internet, the PC industry, and the mobile industry are any guide, public and private investments in the synthetic biology industry will yield extraordinary returns on investment from both an economic and societal standpoint.

The McKinsey report also says that biology could ultimately produce 60% of the physical inputs to the global economy, and solve 45% of the world’s disease. These impacts on the environment and the wellness of all the world’s people are truly priceless. For many in the synthetic biology community, who share a passion for using synthetic biology to build a better, more sustainable universe, this is the real goal.

Even if the lofty projections about synthetic biology and the coming bioeconomy turn out to be only partially true, the opportunities for innovators, investors, and the public remain spectacularly large.

Follow me on twitter at @johncumbers and @synbiobeta. Subscribe to my weekly newsletters in synthetic biology Thank you to Stephanie Michelsen and Kevin Costa for additional research and reporting in this article. I’m the founder of SynBioBeta, and some of the companies that I write about are sponsors of the SynBioBeta conference and weekly digestHere’s the full list of SynBioBeta sponsors.

Originally published on Forbes: https://www.forbes.com/sites/johncumbers/2020/05/30/mckinsey-report-4-trillion-gold-rush-bioeconomy-synthetic-biology/

2
John Cumbers

John Cumbers

John Cumbers is the founder of SynBioBeta. John is passionate about education and on the use and adoption of biological technologies. He has received multiple awards and grants from NASA and the National Academy of Sciences for his work in the field. John has been involved in multiple startups such as those producing food for space, microbes to extract lunar and martian resources, and hoverboards! John is an active investor through the DCVC SynBioBeta Fund and his synthetic biology syndicate on AngelList.

Stephanie Michelsen

Stephanie Michelsen

Stephanie Michelsen is pursuing her M.Sc. in Biotechnology at the University of Copenhagen, Denmark. She recently got accepted as an International Innovation Program (2ip) fellow, a program designed to connect Danish life science students with the biotech start-up industry in the Bay Area. She is therefore currently living in the San Francisco Sunset district with four other Danish students learning about biotech entrepreneurship. As a 2ip fellow and as a writer and editor for SynBioBeta she is fortunate enough to further explore her interest in the many possibilities of synthetic biology.

Kevin Costa

Kevin Costa

As Editor and Program Manager, Kevin leads SynBioBeta's digital media content, with the goal of telling the story of the people, companies, and ideas shaping the future with biology. Before joining SynBioBeta, Kevin managed the Synthetic Biology Engineering Research Center. His interests include public engagement, science writing, community building, and bikes!

Click here to join our weekly newsletter. We want to hear what you think about this article. Got a tip for our news team? Write to editorial@synbiobeta.com.

Editor’s picks